295 related articles for article (PubMed ID: 32990050)
1. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
Giraud EL; Jessurun NT; van Hunsel FPAM; van Puijenbroek EP; van Tubergen A; Ten Klooster PM; Vonkeman HE
Expert Opin Drug Saf; 2020 Dec; 19(12):1617-1624. PubMed ID: 32990050
[TBL] [Abstract][Full Text] [Related]
2. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
[TBL] [Abstract][Full Text] [Related]
3. Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.
Giraud EL; Thomas PWA; van Lint JA; van Puijenbroek EP; Römkens TEH; West RL; Russel MGVM; Jansen JM; Jessurun NT; Hoentjen F;
Drug Saf; 2021 May; 44(5):581-588. PubMed ID: 33538994
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Machado-Alba JE; Ruiz AF; Machado-Duque ME
Rev Panam Salud Publica; 2014 Dec; 36(6):396-401. PubMed ID: 25711751
[TBL] [Abstract][Full Text] [Related]
5. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Mittal N; Sharma A; Jose V; Mittal R; Wanchu A; Bambery P
Rheumatol Int; 2012 Mar; 32(3):743-8. PubMed ID: 21161534
[TBL] [Abstract][Full Text] [Related]
6. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
8. A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
Cho SK; Sakai R; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Tanaka Y; Nakajima A; Yasuda S; Ihata A; Ezawa K; Won S; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Miyasaka N; Bae SC; Harigai M; ;
Mod Rheumatol; 2014 Jul; 24(4):572-9. PubMed ID: 24320747
[TBL] [Abstract][Full Text] [Related]
9. Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data.
Kwon M; Joung CI; Shin H; Lee CC; Song YS; Lee YJ; Kang S; Kim JY; Lee S
Sci Rep; 2024 Feb; 14(1):2660. PubMed ID: 38302579
[TBL] [Abstract][Full Text] [Related]
10. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Velthuis K; Jessurun NT; Nguyen TDM; Scholl J; Jansen JRG; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE
Expert Opin Drug Saf; 2023; 22(6):485-492. PubMed ID: 36683590
[TBL] [Abstract][Full Text] [Related]
11. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
12. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
16. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
Blomqvist P; Feltelius N; Ekbom A; Klareskog L
J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
[TBL] [Abstract][Full Text] [Related]
18. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan.
Takeuchi T; Ishida K; Shiraki K; Yoshiyasu T
Mod Rheumatol; 2018 Jan; 28(1):48-57. PubMed ID: 28649878
[TBL] [Abstract][Full Text] [Related]
20. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
